Phaseline

Targets › ERCC2

ERCC2 (General transcription and DNA repair factor IIH helicase subunit XPD): drug programs, companies and trials

2 programs from 2 companies in 12 trials: 9 Phase 4, 2 Phase 2, 1 Phase 1; Cardiovascular, Immunology, Infectious disease; next expected readout Dec 2027.

ATP-dependent 5'-3' DNA helicase. Component of the general transcription and DNA repair factor IIH (TFIIH) core complex, not absolutely essential for minimal transcription in vitro. (UniProt, P18074)

Open in Phaseline: the race on ERCC2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bausch Health AmericasClindamycin
Bacterial 70S ribosome inhibitor
ERCC1, ERCC2Phase 4Acne Vulgaris; Skin Infection; Infection Control / Methods; Surgical Site Infection …Dec 2027
M.D. Anderson Cancer CenterTrabectedin
Alkylating agent - binds DNA and inhibits transcription, particularly affecting transcript
ERCC2, ERCC3Phase 2Uterine Leiomyosarcoma; Soft Tissue SarcomasDec 2027

Conditions

Acne Vulgaris (2) Skin Infection (1) Infection Control / Methods (1) Surgical Site Infection (1) Endocarditis Infective (1) Wisdom Tooth Removal (1) Cat Bite (1) Staphylococcus Aureus Bacteremia (1) Aortic Surgery (1) Uterine Leiomyosarcoma (1) Soft Tissue Sarcomas (1)

Modalities

small molecule (1), mixed (1)

Companies

Bausch Health Americas (1) M.D. Anderson Cancer Center (1)

Related targets

ERCC1 (1) ERCC3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.